Comparing Australia and New Zealand MS Populations Project (COMPANZ)
COMPANZ aims to explore the long-term effects of MS disease modifying treatments (DMTs) by comparing people with MS living in Australia and New Zealand, because access to MS treatment programs differs between countries. They will examine the links between MS medication use and other long-term health outcomes, including disability, employment, and socio-economic outcomes such as income, and educational opportunities.
Participants are invited to be involved in this new collaborative study being conducted by:
- Dr Deborah Mason, a neurologist from Canterbury District Health Board New Zealand
- Professor Bruce Taylor, a neurologist from the University of Tasmania, Australia
- Dr Suzi Claflin, a post-doctoral research fellow from Menzies Institute for Medical Research, Australia
Taking part in the COMPANZ trial
- Must have been involved with the 2006 MS Prevalence Study
- Have indicated that you would like to be contacted for further studies
To find out if you are eligible to participate please email Suzi Claflin.
For further information
Introduction – Comparing Australia and NZ MS Populations Project
Participant Information – Comparing Australia and NZ MS Populations Project